:#+OPTIONS: org-inline-image-overlays:t org-image-actual-width:nil
#+ATTR_HTML: :width 40px
* antibacterial targets :l:
** Cell Wall Biosynthesis
*** Beta-lactam antibiotics
**** Why do β-lactam antibiotics inhibit penicillin-binding proteins (transpeptidase)? :ignore:
(D-Ala)₂ looks a lot like penicillin, so PBP-Serine-OH reacts with penicillin instead of (D-Ala)₂ on the growing peptidoglycan polymer. β-lactam antibiotics irreversibly inhibit PBP.
**** β-lactamase hydrolysis of penicillin :ignore:
β-lactamase-Ser-OH opens β-lactam ring at carbonyl
**** resistance :ignore:
***** causes
production of β-lactamase by bacteria
***** mechanism
β-lactamase hydrolyzes the β-lactam ring
**** SAR :ignore:
***** overcoming resistance
- add bulky functional groups to the acyclic amide to sterically inhibit β-lactamases
- electron withdrawing group to acyclic amide
***** acid stability
- electron withdrawing group as substituent to acyclic amide
- adding acid stability allows the drug to have good oral bioavailability
***** both acid stability and β-lactamase resistance
sterically bulky /and/ electron withdrawing group substituted on the acyclic amide
**** classes :l:
***** Penicillins
****** types by structure :l:
******* methicillin
******* isoxazole
******* ureidopenicillin
******* acidic penicillin
******* amino penicillin
****** Penicillin G/V
******* Pen G IV
******** common use
CNS manifestations of syphillis
******** syphillis—causative agent
Treponema pallidum
******* Pen G IM PCNs
******** common use
major Strep infections
******* Pen V PO
- strep throat
- some dental infections
****** semi-synthetic penicillins :l:
******* Naficillin
******** indication
nosocomial MSSA
******* Methicillin
******* Oxacillin
stable toward acid and β-lactamase
Bactocil
******** brand
******* Dicloxacillin
stable toward acid and β-lactamase
******** brand
- Dycill
- Pathocil
******* Amoxicillin/Ampicillin
******** coverage
- Strep. pneumo. and Intermediate S. pneumo in higher dosage
******** Ampicillin
- DOC for listeria
****** Acidic penicillins :l:
******* Ticarcillin
******** coverage
- Pseudomonas
- Gram-
****** “isoxazole penicillins”
- oxacillin
- dicloxacillin
****** Ureidopenicillins
******* Piperacillin
******** spectrum
- Pseudomonas aeruginosa
- Enterococcus
****** Aminopenicillins
******* ampicillin
******** indication
drug of choice for /Listeria/ infections
******* amoxicillin
******** prodrug
form with unionized amino groups, which would be ionized at physiological pH
****** MSSA
sensitive staph aureus (MSSA); this is /not MRSA/
******* practical uses
bactericidal against staph
****** questions
******* PO only?
- Penicillin V
******* IV only?
- Timentin
- Zosyn
****** physiochemical properties
******* acid-base attacks
acid-catalyzed ring opening of the strained Penam nucleus
******* pH environment
- Stable between 6-7.2
- Do not place in highly acidic or basic environment
****** combinations :l:
******* Amoxicillin + Clavulanic acid
******* Ticarcillin + Clavulanic Acid
******* Ampicillin + Sulbactam
******* Piperacillin + Tazobactam
***** Cephalosporins
****** general structure
[[./cephalosporin_general_structure.png]]
****** avoid with TPN or divalent metal ions :ignore:
Ceftrioxone (Rocephin)
****** SAR :ignore:
******* free carboxylic acid at C2
- must be present for antibacterial activity
- prodrugs formed by making an ester with the carboxylic acid at C2
****** 1st generation
******* Cefazolin
******** brand
Ancef
******** ROA
IV
******** indication
prophylaxis of Staphylococcus infection, esp. in surgery
******** spectrum
Gram-(+)
******* Cephalexin
******** brand
Keflex
******** ROA
PO
******** spectrum
- Gram-(+)
- modest activity against Gram-(-)
******* Cefadroxil
******** ROA
PO
******* Cephalothin
******** ROA
IV
****** 2nd generation
******* Cephamycins
******** common structural feature
7-methoxy group off the 3-cefem nucleus
******** spectrum
- certain anaerobic bacteria
- Bacteroides fragilis
******** drugs :l:
********* cefoxitin
********* cefotetan
********* cefmetazole
******* NON-cephamycins
******** indications
- COPD/bronchitis
- H. influenzae
******** drugs :l:
********* cefaclor
********** brand
Raniclor
********** ROA
PO
********* cefprozil
********** brand
Cefzil
********** ROA
PO
********* cefonicid
********* cefuroxime
********* cefoxitin
****** 3rd generation
******* common structural feature
2-amine-1,3-thiazole ring
******* ROA
parenteral
******* drugs
******** IV :l:
********* Ceftriaxone 
********** brand
Rocephin
********** DOC for
Neisseria meningitis
********** usage
don’t administer within 24h of calcium products e.g. TPN
********* Cefotaxime
********** brand
Claforan
********* Ceftazidime
********** brand
- Fortaz
- Tazicef
********** coverage
- potent inducer of β-lactamase, especially in Enterobacter
- Pseudomonas
- Gram-(-) rods
******** “super hero gen”
********* ceftazidime/avibactam
********* ceftolozane/tazobactam
******** PO :l:
********* Cefdinir
********* Cefditore
********* Cefixime
********* Ceftibute
********* Cefoperazone
********* Ceftizoxime
********** brand
Cefizox
****** 4th generation
******* drugs
******** Cefepime
********* ROA
Cefepime
********* brand
Maxipime
****** 5th generation
******* drugs :l:
******** Ceftaroline
********* brand
- Teflaro
- Fosamil
********* ROA
IV
********* spectrum
- MRSA
- S. pneumoniae
- K. pneumoniae
- E. coli
****** spectrum
****** non-spectrum (organisms on which Cephalosporins have no effect)
- LAME
- Listeria
- Atypicals
- MRSA
- Enterococci
***** Carbapenems
****** cilastin
inhibits renal dehydropeptidase-1, which hydrolyzes the β-lactam ring of imipenem
******* Primaxin
Imipenem + Cilastin
****** drugs :l:
******* Imipenem
******* Meropenem
******* Doripenem
******* Ertapenem
******** brand
Invanz
****** indications
- Basically covers everything (including anaerobes, atypicals, nasty GNRs, PA, etc).
- Ertapenem (Invanz) barely covers anything
****** non-indications
- MRSA
***** Carbacephems
***** Monobactams
****** drugs :l:
******* Aztreonam
******** ROA
IV
******** coverage
- Gram-
**** allergy
***** structures that cause reactivity
- β-lactam ring structure
- S on the β-lactam ring
- R1 group side chains
**** structures
***** [[./isoxazole_ring.png]]
isoxazole ring
***** [[./ampicillin.png]]
ampicillin
***** [[./cephalosporin_core_structure.png]]
cephalosporin
***** nuclei of each class
****** [[./cefem_nucleus.png]]
cefem nucleus
****** [[./penam_nucleus.png]]
penam nucleus
****** [[./monobactam_nucleus.png]]
monobactam nucleus
*** Glycopeptide
**** drugs :l:
***** Vancomycin
**** spectrum
- MRSA
- VRE
**** non-spectrum
Gram-(-)
*** Glycolipopeptide
**** Telavancin
**** Oritavancin
**** Dalbavancin
*** Miscellaneous
**** Cycloserine
***** side effects
CNS disturbances
***** MOA
- inhibits 2 key enzymes
  - D-alanine racemase
  - D-alanine synthase/ligase
- blocks peptidoglycan cross linking of the myobacterial cell wall
***** indication
TB infections
***** SAR
rigid analog of D-alanine
**** Isoniazid
***** indication
TB infections
**** Ethionamide
**** Ethambutol
**** Teicoplanin
*** Lipopeptides :l:
**** Daptomycin
***** MOA
- lipophillic decanoyl side chain inserts into bacterial cell membrane
- bactericidal
***** indications
***** spectrum
- MRSA
- VRE
**** Polymixins
***** MOA
- detergent-like effect
- loss of cell membrane integrity
- bactericidal
***** indications
- IV agent used to kill nasty infections
- Gram(-) bacteria
***** spectrum
- MDR acinetobacter
- Pseudomonas
- Klebsiella
**** Bacitracin
***** spectrum
Gram(+)
***** formulation
- topical
- only available in combinations
  - with Polymyxin B (Polysporin™)
  - with Polymyxin B and Neomycin (Neosporin®)
**** Colistin
** Cytoplasmic Membrane 
** DNA Biosynthesis
*** fluroquinolones
**** MOA
- inhibits topoisomerase II (DNA gyrase), which replicates, transcribes, and repairs bacterial DNA
- inhibits topoisomerase IV, which partitions DNA during cell division
- bactericidal
- concentration-dependent
**** structure
[[./fluroroquinolone_keto_enol_structure.png]]
**** SAR
****** CNS side effects
caused by a basic ring system substituent on C-7—pyrrolidine, piperazine, substituted piperazine, bicyclic ring system
****** C-3
must have a carboxylic acid at C-3
****** N-1
1,4-dihydroquinolone portion is essential because it freezes the drug in the correct keto-enol tautometer
****** chelation
- carboxylic acid at C-3
- keto at C-4
chelates divalent and trivalent cations; decreases oral bioavailability
****** fluorine subsitutent
******* at C-6
- good activity against Gram(-) bacteria
- broad spectrum activity
******* at C-6 and C-8
- improves drug absorption and half-life
- increases drug-induced photosensitivity
**** drugs :l:
***** levofloxacin
****** brand
Levaquin
****** spectrum
- Gram(-)
- atypicals
- S. pneumoniae
- sensitive Staph.
***** gemifloxacin
****** indications
- very poor activity against Pseudomonas aeruginosa
****** spectrum
respiratory pathogens
***** moxifloxacin
****** brand
Avelox
****** indications
- respiratory pathogens, including S. pneumoniae
****** non-indicaations
UTIs
***** ciprofloxacin
****** brand
Cipro
****** spectrum
- enteric Gram(-) rods
- doesn’t cover
  - S. pneumoniae
****** indications
anthrax
****** non-indications
S. pneumoniae
***** norfloxacin
****** brand
Noroxin
****** indication
UTIs only
****** spectrum
Gram(-)
**** warnings
ALL QUINOLONES SHOULD NOT BE CO-ADMINISTERED WITH TPN AND DIVALENT METAL IONS
*** metronidzole
*** nitrofurantoin
** folate synthesis inhibitors
*** drugs :l:
**** dapsone
**** trimethoprim/sulfamethoxazole
*** spectrum
- MRSA
- Stenotrophomonas maltophilia
** DNA-dependent RNA Polymerase
** RNA inhibitors :l:
*** rifamycins :l:
**** rifampin
**** rifabutin
**** rifapentine
** Protein Biosynthesis Inhibitors
*** 30S :l:
**** tetracyclines
***** SAR
chelation of divalent and trivalent caations occur at C-{10, 11, 12}
***** drugs :l:
****** tetracycline
******* indication
skin and skin-structure infections in people ≥18 yo
******* class
glycylcycline
******* spectrum
- MSSA and MRSA
- Enterococcus faecalis (vancomycin-susceptible strains)
- Streptococcus species
- E. coli
- Bacteroides fragalis (an anaerobe)
****** doxyycline
******* ROA
- PO
- IV
******* spectrum
- aytpicals
  - Chlamydia
  - Chlamydophilia
  - M. pneumoniae
- tick borne diseases
  - Ehrlichia
  - Ricksettsoses
  - Vibrio cholerae, V. vulnificus
  - community associated MRSA
  - S. pneumniae
  - anthrax
****** minocycline
******* adverse effects
- dizziness
- vertigo
******* spectrum
community associated MRSA
******* indicaitons
- acne
- dental work
****** tigecycline
******* brand
Tygacil
******* ROA
IV only
******* non-spectrum
Pseudomonas
****** ervacycline
****** omadacycline
***** adverse effects
- discoloration of developing
- CNS effects because its high lipid solubility allows it to enter CNS
***** mechanisms of resistance
- efflux of antibiotic from microbe
- decreased penetration into microbe
- bacterial production of a ribosome protective protein
**** aminoglycosides
***** MOA
- concentration-dependent bactericidal killing
- binds to 30S ribosomal subunit, intefering with protein synthesis
***** mechanisms of resistance
- phosphorylation of hydroxyl groups
- adenylation of hydroxyl groups
- acetylation of amino groups
***** chemistry
- highly polar---positive charge
- multiple hydroxyl groups
- lacks lipid solubility
- multiple basic nitrogens
***** drugs :l:
****** plazomicin
****** gentamicin
******* spectrum
- Gram-(-)
- P. aeruginosa
****** tobramycin
******* spectrum
P. aeruginosa
****** amikacin
******* spectrum
- high activity on nasty GNRs
- P. aeruginosa
****** streptomycin
***** spectrum
only Gram-(-)
***** toxicity
- nephrotoxicity
- ototoxicity
- neurotoxicity
***** combination
used /synergistically/ in combination with beta-lactam antibiotics or glycopeptides
*** 50S :l:
**** macrolides
***** drugs :l:
****** erythromycin
******* disadvantages
- acid catalyzed degradation in the stomach
- less than desirable bioavailability
- side effects
  - GI
  - hepatotoxicity
- significant resistance
****** clarithromycin
******* ROA
PO only
****** azithromycin
****** telithromycin
******* brand
Ketek
******* spectrum
macrolide-resistant pathogens including S. pneumoniae
******* toxicity
- hepatotoxicity
- prolongation of QTc interval
******* SAR
C-6 methoxy improves acid stability
****** fidaxomycin
******* brand
Dificid
******* spectrum
- narrow
- mainly used against C. dificile
***** structure
large cyclic ester ring
[[./macrolide_structure.png]]
***** MOA
- bacteriostatic
- blocks translation by binding to 50S ribosomal subunit
***** non-indications
- respiratory tract infections---use alternative agents for Moraxella, atypical pneumonia organisms (Mycoplasma, Chlamyida, Legionella)
- use alternative agents for S. pneumoniae---erythromycin is resistant
***** indications
- acne
- dental infections
- H. influenzae infections
***** SAR
****** gut
- intramolecular nucleophillic attack by hydroxyl on the carbonyl group results in an inactive drug
- unstable due to acid catalyzed ring opening in the stomach
****** dosage designs
- erythromycin stearate---stearate salt off the dimethylamino grouup on the desoamine ring is less soluble in acidic media and hence more stable to degradation in the stomach
- erythromycin estolate---salt is less soluble in acidic media and hence more stable to acid degradation in the stomach
- erythromycin lactobionate---water soluble salt for parenteral administration
- erythromycin ethylsuccinate---esters of the hydroxyl group on the desoamine ring creates decreased water solubility to mask the bitter taste of erythromycin in pediatric dosage forms
****** 
***** spectrum
atypicals
**** lincosamide
***** chemistry
- 8 carbon sugar, thiomethyl amino-octoside (O-thio-lincosamide)
- weakly basic and forms hydrochloride salts
***** drugs :l:
****** clindamycin
******* brand
Cleocin
******* spectrum
- Gram-(+)
- Strep., esp. in patients allergic to beta-lactams
******* SAR
substitution of chloride for hydroxy group improves oral bioavailability; more lipophillic
******* adverse effects
potentially fatal colitis
****** lincomycin
******* brand
Lincosin
***** spectrum
- anaerobes
- MRSA
**** streptogramins
***** drugs :l:
****** quinupristin/dalfopristin
******* ROA
IV
******* brand
Synercid
******* composition
Synercid® is quinupristin:dalfopristin in a 30:70 ratio
******* spectrum
- MRSA
- VRSA
- VRE faecium---not /faecalis/
- Gram-(+)
****** MOA
- binds to 50S ribosomal subunit
- bacteriostatic
***** spectrum
Gram-(+)
**** oxazolidinones
***** drugs :l:
****** linezolid
******* brand
Zyvox
******* spectrum
Gram-(+)
******* interactions
- since linezolid is a MOA inhibitor...
  - tyramine, phenylalanine, tyrosine, tryptophan
  - adrenergic agents
  - serotonergic agents
  - beer containing tyramine
- myelosuppressive drugs
****** tedizolid
******* brand
Sivextro
***** warnings
- therapy more than 2 weeks increases risk of thrombocytopenia/pancytopenia
- not for use in endocarditis/endovascular infections
***** spectrum
- MRSA
- VRE
**** nitroimidiazoles
***** drugs :l:
****** nitrofurantoin
******* brand
- Macrodantin
- Macrobid
****** metronidazole
******* brand
Flaygyl
******* adverse effects :l:
******** disulfiram-like reaction
abstain from alcohol during therapy for 72 hours post-therapy because metronidazole inhibits aldehyde dehydrogenase
******** GI---n/v/d; metallic taste
******** neuropathy
******* indications
- Bacterioides fragilis
- Clostridium difficile colitis
- Heliobacter pylori
- Trichomonas vaginalis
- Amebiasis
- Giardiasis
****** tinidazole
******* brand
Tindamax
***** MOA
- bactericidal
- nitro group is reduced in anaerobic pathogens to yield a highly reactive nitro radical anion that kills the pathogens
***** spectrum
anaerobes
**** fosfomycin
***** spectrum
- Pseudomonas
** Tetrahydrofolic Acid
* normal flora
** oral cavity
- Viridians streptococci
- Peptococcus
- Petpostreptococcus
- Eikenella
- Haemophilus
** upper airways
- S. pneumoniae
- S. pyogenes
- Neisseria sp.
- H. influenzae
- S. aureus
** lower airway
normally sterile
** skin
- S. epidermidis
- S. aureus
- Propionibacterium
- Corynebacterium
** stomach
H. pylori
** small intestine
*** proximal
- Lactobacillus
- Enterococcus
*** distal
- Lactobacillus
- Enterococcus
- Bacteroides
- coliforms (E. coli, Enterobacter, Citrobacter)  
** large intestine and rectum
- Bacteroides
- Fusobacterium
- Bifidobacterium
- Clostridium
- Enterococcus
- Lactobacillus
- S. bovis
- coliforms (E. coli, Enterobacter, Citrobacter)
** genitourinary tract
- Lactobacillus
- Streptococcus
- E. coli
- Corynebacterium
- Candida
* therapeutics
** bactericidal drugs
- Vancomycin
- Fluoroquinolones
- Penicillin
- Aminoglycosides
- Cephalosporins
- Metronidazole
** bacteriostatic drugs
- Erythromycin
- Clindamycin
- Sulfamethoxazole
- Trimethoprim
- Tetracyclines
- Chloramphenicol
** lower respiratory infections
*** community acquired pneumonia
**** diagnostics :l:
***** chest radiography (CXR)
- most common
- looks for
  - infiltrate
  - patchy consolidation
***** pretreatment blood cultures
test for etiology
***** biomarkers
- C-reactive protein (CRP)
- procalcitonin (PCT)
**** pathogens
- Chlamydophilla pneumoniae
- Haemophilus influenzae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Streptococcus cpneumoniae
**** assessment
***** CURB-65
- confusion : 1 point
- BUN ≥20 mg/dL : 1 point
- RR ≥30 bpm : 1 point
- SBP <90 mm Hg or DBP ≤60 mm Hg : 1 point
- age ≥65 : 1 point
**** treatment
***** categories
****** no antibiotic use in the past 3 months and previously healthy
- macrolide
- doxycycline
****** risk factors for drug-resistant /S. pneumoniae/ or comorbidities
- β-lactam + { macrolide, doxycyline }
- respiratory quinolone monotherapy
***** based on CURB-65 score
- 0-1: monotherapy in patients without cormobodities
- 2: combination antibiotics or quinolone; inpatient, no ICU admission
- 3-4: beta-lactam + {macrolide, quinolone}; also requires inpaatient ICU admission
*** hospital acquired pneumonia
**** goal trough of vancomycin
15-20 mcg/mL
**** causative agents
- Pseudomonas sp.
- Acinetobacter sp.
- Escherichia sp.
- Klebsiella sp.
- Staphylococcus aureus
** step wise approach to ID
1. Establish presence and severity of infection
2. Confounding factors in diagnosis of infection
3. Establish site of infection
4. Determine likely pathogens
5. Understand microbiologic test and susceptibility of organism
6. Determination of isolate pathogenicity
7. Evaluate antimicrobial toxicities, cost of therapy
8. Determine most appropriate route of administration and dosing
9. Keep in mind pharmacokinetics/pharmacodynamics
10. Assess for antimicrobial failure and recognize pertinent host factors 
** common hepatically cleared drugs
- ceftriaxone
- clindamycin
- isoniazid
- macrolides
- metronidazole
- naficillin
- rifamycins
- tetracyclines
** antibiotics with post-antibiotic effect
- aminoglycosides
- vancomycins
- fluoroquinolones
- daptomycin
** antibiotics to avoid in pregnancy
- SAFE Moms Take Really Good  Care
- Sulfonamides
- Aminoglycosides
- Fluoroquinolones
- Erythromycin
- Metronidazole
- Tetracyclines
- Ribavirin
- Griseofulvin
- Chloramphenicol 
** side chain similarities
*** cephalosporin similar to penicillin, ampicillin, amoxicillin?
cephalexin
*** carbapenems similar to *cillin?
none
*** cephalosporins similar to each other?
- cefoxitin
- ceftriaxone
- cefotaxime
** otitis media
*** treatment
**** initial
- first line: amoxicillin 80-90 mg/kg/d PO in 2 divided doses
- alternative: amoxicillin/clavulanate
- second-line: cefuroxime (2nd gen cephalosporin) or 3rd gen cephalosporin like cefdinir, cefpodoxime, ceftriaxone
**** treatment failure
amoxicillin/clavulanate 90mg-6.4mg/kg/d PO in 2 divided doses
*** causative agents
- H. influenzae
- S. pneumoniae
- M. catarrhalis
** rhinosinusitis
*** treatment
**** children
amoxicillin-clavulanate 45mg/kg/d PO BID
**** adults
amoxicillin-clavulanate 500mg/125mg PO TID or 875/125mg PO BID
**** β-lactam allergy
- doxycycline 100 mg PO BID or 200 mg PO QD
- levofloxacin 500 mg PO QD
*** pharyngitis
**** most common cause
Group A Streptococcus---S. pyogenes
**** treatment
1. penicillin VK x10d
2. penicillin G IM x1
3. amoxicillin 50 mg/kg QD (max 1g) x10d
* no coverage against strep pneumoniae
Cipro
* moxifloxacin
not a drug for UTIs
* gastrointestinal infections
** dystentery
- Y. enterocolitica 
- EHEC (Enterohemorrhagic E. coli)
- Campylobacter spp.
- Salmonella spp.
- Shigella spp.
** Guillain-Barre syndrome
C. jejuni
** HUS
*** acronym
hemolytic uremic syndrome
*** increases HUS risk
use of a fluroquinolone or Bactrim may increase the risk of HUS by increasing production of Shiga-like toxin
** severe diarrhea
>8 stools per day
** infectious diarrhea
*** treatment
**** fluid and electrolyte replacement
***** oral rehydration
Pedialyte, Rehydralyte, Infalyte, Oralyte, WHO formula
***** severe dehydration
****** definition
≥10% body weight loss
**** bismuth subsalicylate
***** brand
Pepto-Bismol
***** warnings
avoid in children because it may cause Reye’s syndrome
***** dosing
- 30 mL (2 tabs) q30-60min
- max 8 doses q24h
**** when antibiotic therapy recommended
- Severe diarrhea 
- Moderate-to-severe cases of traveler’s diarrhea
- Most cases of febrile dysenteric diarrhea
- Culture-proven bacterial diarrhea in high-risk patients
- Severe cases of cholera 
- ETEC 
- Pregnancy
- Immunocompromised patients
- Prolonged illnesses 
- Infants <3 months old
- Patients with fever and signs and symptoms of sepsis
**** watery diarrhea
***** ETEC
- Ciprofloxacin (Cipro) 750 mg PO x1
- azithromycin (Zithromax) 1000 mg PO OR 500 mg QD x3d
- rifaximin 200 mg PO TID x3
***** Vibrio cholerae
doxycycline 300 mg PO x1
**** dysenteric diarrhea
***** Campylobacter sp.
- azithromycin 500 mg PO QD x3d
- erythromycin 500 mg PO q6h x3d
***** Salmonella nontyphoidal, Shigella sp., Yersinia sp.
- Ciprofloxacin 750 mg PO QD
- Levofloxacin 500 mg PO QD
** traveler’s diarrhea
*** prophylaxis :l:
**** Bismuth subsalicyclate
***** brand
Pepto-Bismol
***** dosage
524 mg (2 tabs or 2 tbsp) PO QID
**** fluoroquinolones
**** doxycyline
**** azithromycin
**** rifaximin
***** indication
200 mg pO TID only for Latin America and Africa
***** spectrum
only effective against E. coli
*** treatment
**** symptomatic relief
***** loperamide
****** brand
Immodium
****** dose
4 mg x1 then 2 mg each subsequent stool; max 16 mg/day
**** empiric treatment
***** fluroquinolones
****** ciprofloxacin
****** levofloxacin
****** norfloxacin
800 mg PO x1d or 400 mg PO BID x3d
***** azithromycin
****** dose
1 g PO x1 or 500 mg PO QD x3
****** indication
South and Southeast ASia
***** Rifaximin
****** dose
200 mg PO TID x3
****** indication
Mexico and Jamaica
** food poisoning
*** Enterotoxigenic poisonings
- Bacillus cereus
- Clostridium botuilism
- Clostridium perfringens (type A)
- Staphylococcus aureus
